



Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552]

Thomas Yau^{1,*}, Chiun Hsu^{2,3}, Tae-You Kim⁴, Su-Pin Choo⁵, Yoon-Koo Kang⁶, Ming-Mo Hou⁷, Kazushi Numata⁸, Winnie Yeo⁹, Akhil Chopra¹⁰, Masafumi Ikeda¹¹, Ryoko Kuromatsu¹², Michihisa Moriguchi¹³, Yee Chao¹⁴, Huanyu Zhao¹⁵, Jeffrey Anderson¹⁵, Christine Dela Cruz¹⁵, Masatoshi Kudo¹⁶

¹Department of Medicine, University of Hong Kong, Hong Kong, China; ²Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; ³Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; ⁴Division of Medical Oncology, Seoul National University, Seoul, South Korea; ⁵Division of Medical Oncology, National Cancer Centre, Singapore; ⁶Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea; ⁷Division of Hematology and Oncology, Chang Gung Memorial Hospital, Taipei, Taiwan; ⁸Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan; ⁹Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China; ¹⁰Department of Medical Oncology, OncoCare Cancer Centre, Singapore; ¹¹Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; ¹²Department of Medicine, Kurume University Hospital, Fukuoka, Japan; ¹³Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan; ¹⁴Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; ¹⁵Bristol-Myers Squibb, Princeton, NJ, USA; ¹⁶Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan

It has come to our attention that there is an error in Table 4 of our manuscript. In the row ‘Chemotherapy’, the values for the Asian cohort should read 37 (44), rather than 37 (43). Please see corrected Table below:

Table 4. Subsequent therapy after nivolumab progression.

Therapy	ITT population (n = 182)	Asian cohort (n = 85)
Any subsequent therapy, n (%)	94 (52)	53 (62)
Radiotherapy	40 (22)	22 (26)
Surgery	17 (9)	9 (11)
Systemic therapy	62 (34)	36 (42)
Chemotherapy	45 (25)	37 (44)
Targeted therapy	37 (20)	20 (24)
Immune checkpoint inhibitor	9 (5)	5 (6)
Other immunotherapy	5 (3)	5 (6)
Experimental therapy	18 (10)	9 (11)
Other	10 (5)	9 (11)
Local therapy	34 (19)	24 (28)
TACE	24 (13)	19 (22)
HAI chemotherapy	5 (3)	5 (6)
Other	10 (5)	4 (5)
Radiofrequency ablation	3 (2)	3 (4)

HAI, hepatic artery infusion; ITT, intent-to-treat; TACE, transcatheter arterial chemoembolisation.

* DOI of original article: <http://dx.doi.org/10.1016/j.jhep.2019.05.014>.

* Corresponding author: Address: 4/F, Professional Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Tel.: +852 9142 3948. E-mail address: tyaucc@hku.hk (T. Yau).

